Psoriatic Arthritis

Findings showed the rates of TEAEs were generally similar between upadacitinib 15 mg and active comparators in RA and PsA.

A national survey provides insight into the prevalence of arthritis based on race in the US from 2011 – 2018.

A study describes the structure and function differences of the Achilles tendon for PsA patients who self-report pain and those who don’t.

Data showed a significant reduction in pain for patients with psoriatic arthritis and inadequate response to TNF treated with guselkumab compared with placebo.

Treatment with guselkumab led to rapid, clinically meaningful improvements in disease activity among patients with severe psoriatic arthritis, which were maintained through 2 years.

Results revealed cDAPSA can help providers accurately measure the level of disease activity in patients and predict whether the patient will have radiographic progression.

Patients with psoriasis on biological agents might have a lower PsA risk than those on methotrexate, but patients on topical therapy have an even lower risk, a study found.

Among patients with PsA, men tend to present more peripheral joint movement, and women tend to exhibit more axial involvement, a new study found.

Adults with active PsA treated with guselkumab exhibited durable achievement of study endpoints associated with disease control, irrespective of baseline characteristics.

Patients in the active counseling group were more likely to achieve low disease activity or remission.

cfPWV values were significantly higher in patients with PsA compared with controls, even after adjusting for confounders.

The approvals were based on data from well-controlled studies of the drug in adult patients with PsA and RA.

In a new study, 16% of patients with RA and 22% with PsA had sleeping issues during the last week.

Benjamin J. Smith, DMSc, PA-C, discusses the importance of defining comorbidities in diagnosing PsA, as well as prescribing biologics.

After initiating treatment with ixekizumab, tender and swollen joint counts, pain, fatigue, and body surface area affected by psoriasis were significantly improved.

Combining algorithms SCORE2 and QRISK3 created the best predictive model to predict the cardiovascular risk for patients with PsA.

These data highlight the role of the National Health Service, though the relationship between socio-economic background and health outcomes remains complex.

This analysis may require further research to determine whether other treatment-resistant depression or severe depression definitions are specifically associated with inflammatory joint disease.

Those with coexisting PsA and atopic dermatitis needed to switch to a higher number of biologics to achieve disease control.

Both overall TEAEs and serious TEAEs were numerically higher in those receiving upadacitinib compared with adalimumab.

Patients often rely on opioids a year before and a year after a diagnosis of ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis.

Using a cut-off value of 7.1 kPA for liver stiffness, results of the transient elastography yielded 100% sensitivity and 68% specificity among this patient population.

Treatment with risankizumab was shown to be an effective strategy among patients with PsA regardless of varying demographic and psoriatic disease characteristics through 1 year.

Post-treatment with risankizumab, the cDAPSA score, PGA score, and PASI score substantially decreased among a cohort of patients with psoriatic arthritis.

A pooled analysis revealed a loading-dose regimen, especially for patients receiving secukinumab 150 mg for PsA, increases the odds of disease improvement.